etoposide has been researched along with Leukemia, Myeloid in 313 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (5.43) | 18.7374 |
| 1990's | 145 (46.33) | 18.2507 |
| 2000's | 134 (42.81) | 29.6817 |
| 2010's | 17 (5.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mimaki, Y; Sakagami, H; Sashida, Y; Yokosuka, A | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Hattori, T; Naito, M; Nishikawa, K; Watanabe-Takahashi, M | 1 |
| Altman, J; Frankfurt, O; Mehta, J; Pantiru, M; Trifilio, S; Zhou, Z | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Amadori, S; Berneman, Z; De Fabritiis, P; de Witte, T; Falzetti, F; Fazi, P; Guimaraes, JE; Halkes, CJ; Ho, AD; Karrasch, M; Latagliata, R; Lübbert, M; Magro, D; Marie, JP; Muus, P; Salih, HR; Selleslag, D; Specchia, G; Stasi, R; Suciu, S; Thomas, X; Venditti, A; Vignetti, M; Willemze, R | 1 |
| Chen, Y; Fang, J; Li, SS; Yang, LJ; Zeng, LL; Zhang, BP; Zhao, J | 1 |
| Cosio, S; Gadducci, A; Lanfredini, N | 1 |
| Adachi, S; Goto, H; Horibe, K; Ito, E; Iwamoto, S; Kinoshita, A; Koh, K; Kudo, K; Moritake, H; Nakahata, T; Nakayama, H; Saito, AM; Shimada, A; Taga, T; Takahashi, H; Taki, T; Tawa, A; Terui, K; Toki, T; Tomizawa, D; Watanabe, T | 1 |
| Cross, NA; Haywood-Small, SL; Jordan-Mahy, N; Le Maitre, CL; Mahbub, AA | 1 |
| Chen, JR; Jia, XH; Li, YJ; Wang, H; Wang, JY; Xie, SY; Yi, YJ | 1 |
| Berlanga, JJ; Besalduch, J; Brunet, S; Bueno, J; Esteve, J; Gallardo, D; Guardia, R; Heras, I; Hoyos, M; Llorente, A; Nomdedeu, J; Pérez-García, A; Ribera, JM; Sierra, J; Tormo, M | 1 |
| Carlton, D; Edelman, MJ; Fang, HB; Gojo, I; Nakanishi, T; Ross, DD; Sausville, EA; Shiozawa, K; Tan, M; Wang, WC | 1 |
| Campana, D; Crews, KR; Downing, JR; Gandhi, VV; Pounds, S; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Yang, S | 1 |
| de Bont, ES; Kamps, WA; Koetse, HA; Rings, EH; Stellaard, F; Tissing, WJ; van Vliet, MJ | 1 |
| Amadori, S; Baila, L; de Witte, T; Di Raimondo, F; Fazi, P; Ferrara, F; Labar, B; Liso, V; Mandelli, F; Marie, JP; Marmont, F; Meloni, G; Muus, P; Petti, MC; Stasi, R; Suciu, S; Thomas, X; Vignetti, M; Willemze, R; Zittoun, R | 1 |
| Agha, M; Boyiadzis, M; Foon, KA; Luong, TM; McHayleh, W; Natale, J; Raptis, A; Redner, RL; Schlesselman, JJ; Sehgal, R | 1 |
| Baer, MR; Bansal, H; Bansal, S; Barsoum, J; Battiwalla, M; Blackman, RK; Foley, KP; Giles, FJ; Kelly, K; Lee, KP; Padmanabhan, S; Proia, DA; Rao, M; Sang, J; Swords, R; Tomlinson, GE; Ying, W | 1 |
| Guan, XQ; Huang, LB; Ke, ZY; Luo, XQ; Xu, L; Zhang, XL; Zhang, YC | 1 |
| Baron, E; Basso, G; Beghin, A; Manara, E; Pigazzi, M; Tregnago, C | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Minden, MD; Murray, C; Nixon, S; Saini, L; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Barisone, E; Bertorello, N; Calvillo, M; De Rossi, G; Dufour, C; Lo Nigro, L; Luciani, M; Messina, C; Miano, M; Micalizzi, C; Parasole, R; Petruzziello, F; Pistorio, A; Putti, MC; Varotto, S; Ziino, O | 1 |
| Alonzo, TA; Arceci, RJ; Barnard, D; Gamis, AS; Gerbing, RB; Hathaway, L; Hilden, JM; Loew, TW; Ravindranath, Y; Smith, FO; Sorrell, AD; Taub, JW; Woods, WG | 1 |
| Atkinson, HD; Colovic, M; Colovic, N; Jankovic, G; Kraguljac, N; Radojkovic, M; Stanisavljevic, D; Suvajdzic, N; Tomin, D; Vidovic, A | 1 |
| Gibson, AD | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Belleri, M; Presta, M; Ribatti, D; Vacca, A | 1 |
| Badros, A; Barlogie, B; Morris, C; Tricot, G; Zangari, M | 1 |
| Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H | 1 |
| Barbui, T; Bassan, R; Buelli, M; Chiodini, B; Giussani, U; Lerede, T; Oldani, E; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Baer, M; Becknell, B; Bloomfield, CD; Caligiuri, MA; Crawford, J; Dodge, RK; Farag, SS; Fehniger, TA; George, SL; Larson, RA; Lee, EJ; Schiffer, CA; Silverman, LR | 1 |
| Creutzig, U; Hählen, K; Harbott, J; Huismans, DR; Kaspers, GJ; Pieters, R; Slater, RM; Veerman, AJ; Zimmermann, M; Zwaan, CM | 1 |
| Anderson, JE; Appelbaum, FR; Balcerzak, SP; Chen, IM; Head, D; Johnson, DB; Kopecky, KJ; Luthardt, FW; Norwood, TH; O'Donnell, MR; Willman, CL | 1 |
| Aledo, A; Alonzo, TA; Buxton, AB; Kobrinsky, NL; Lange, BJ; Woods, WG | 1 |
| Allen, PD; Cummings, M; Higginbottom, K; Newland, AC | 1 |
| Berger, SJ; Cooper, BW; Donaher, E; Gerson, SL; Gosky, DM; Green, SB; Hoppel, CL; Ingalls, ST; Lazarus, HM; Li, X; Rosenthal, NS | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ID; Gerbing, RB; Lange, BJ; Loken, MR; Sievers, EL; Smith, FO; Woods, WG | 1 |
| Akao, Y; Hanamura, I; Iida, S; Komura, S; Luo, JM; Miura, K; Naoe, T; Ohishi, N; Ohnishi, K; Ohno, R; Pan, L; Shigeno, K; Ueda, R; Yoshida, H | 1 |
| Aoki, Y; Cioca, DP; Kiyosawa, K | 1 |
| Adamczyk-Cioch, M; Dmoszynska, A; Holowiecki, J; Jamroziak, K; Konopka, L; Kuliczkowski, K; Maj, S; Marianska, B; Mazur, G; Robak, T; Wierzbowska, A; Wrzesien-Kus, A; Zawilska, K | 1 |
| Brunet, S; Bueno, J; Esteve, J; Llorente, A; Oriol, A; Ribera, JM | 1 |
| Beck, JD; Borkhardt, A; Creutzig, U; Harbott, J; Jacobs, U; Langer, T; Leis, T; Metzler, M; Rascher, W; Reichel, M; Reinhardt, D; Repp, R; Ritter, J; Schrappe, M; Stanulla, M; Viehmann, S | 1 |
| Allen, SL; Archer, KJ; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; de la Chapelle, A; Kolitz, JE; Larson, RA; Marcucci, G; Moore, JO; Powell, BL; Ruppert, AS; Tanner, SM; Vardiman, JW; Whitman, SP | 1 |
| Amadori, S; Anak, O; Aul, C; Beeldens, F; Belhabri, A; de Witte, T; Ferrant, A; Hess, U; Jehn, U; Labar, B; Mandelli, F; Muus, P; Oosterveld, M; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R | 1 |
| He, XY; Kalaycio, M; Lichtin, A; Pohlman, B; Rybicki, L | 1 |
| Brumbaugh, H; Buckley, P; DeCastro, CM; Gockerman, JP; Laney, R; Moore, JO; Rizzieri, DA; Stevenson, D; Talbot, J | 1 |
| Burnett, AK; Chopra, R; Clark, RE; Culligan, D; Hunter, A; Kell, WJ; Milligan, DW; Prentice, AG; Rohatiner, A; Yin, JA | 1 |
| Okamoto, Y; Pui, CH; Razzouk, BI; Ribeiro, RC; Shenep, JL; Srivastava, DK | 1 |
| Geissler, K; Hauswirth, AW; Knöbl, P; Sperr, WR; Valent, P; Wimazal, F | 1 |
| Amadori, S; Buccisano, F; Coco, FL; Consalvo, MI; Cudillo, L; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Franchi, A; Lo-Coco, F; Maurillo, L; Mazzone, C; Picardi, A; Tamburini, A; Venditti, A | 1 |
| Creutzig, U; Kaiser, J; Klingebiel, T; Lehrnbecher, T; Reinhardt, D; Varwig, D | 1 |
| Ahlgren, T; Billström, R; Brune, M; Hedenus, M; Höglund, M; Markevärn, B; Nilsson, B; Sallerfors, B; Simonsson, B; Stockelberg, D; Wahlin, A | 1 |
| Alonzo, TA; Aplenc, R; Arndt, C; Barnard, D; Dinndorf, P; Feig, S; Feusner, J; Gerbing, R; Lange, BJ; Seibel, N; Smith, FO; Weiman, M | 1 |
| Ahn, HS; Choi, HS; Han, KS; Kang, HJ; Shin, HY | 1 |
| Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E | 1 |
| Aström, M; Björkholm, M; Hast, R; Hedenius, M; Lerner, R; Liliemark, J; Löfgren, C; Nilsson, I; Paul, C; Rödjer, S; Simonsson, B; Stockelberg, D; Tidefelt, U | 1 |
| Califaretti, N; Crump, M; Gupta, V; Keating, A; Mollee, P; Reddy, V; Song, K; Tsang, R | 1 |
| Baer, MR; Bloomfield, CD; George, SL; Kolitz, JE; Larson, RA; Lee, EJ | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Debatin, KM; Karawajew, L; Liu, J; Meyer, LH; Mohr, A; Stahnke, K | 1 |
| Arthur, C; Bashford, J; Baxter, H; Bradstock, KF; Brighton, T; Cannell, P; Catalano, J; Dunlop, L; Durrant, S; Eliadis, P; Enno, A; Gill, D; Gillett, A; Joshua, D; Juneja, S; Koutts, J; Leahy, M; Lowenthal, RM; Matthews, JP; Schwarer, AP; Szer, J; Taylor, K; Young, GA | 1 |
| Blazek, B; Cerná, Z; Gajdos, P; Hak, J; Hrstková, H; Hrusák, O; Jabali, Y; Kopecná, L; Michalová, K; Procházková, D; Ptoszková, H; Sedlácek, P; Smísek, P; Starý, J; Timr, P; Tousovská, K; Vávra, V | 1 |
| Akamatsu, S; Inoue, K; Nishio, Y; Tsukazaki, H | 1 |
| Behm, FG; Campana, D; Cheng, C; Downing, JR; Evans, WE; Howard, SC; Hudson, MM; Kun, LE; Pei, D; Pui, CH; Raimondi, SC; Razzouk, BI; Relling, MV; Ribeiro, RC; Rivera, GK; Rubnitz, JE; Sandlund, JT | 1 |
| Braess, J; Fiegl, M; Hiddemann, W; Lorenz, I; Schneiderat, P; Schoch, C | 1 |
| Batlle, M; Besalduch, J; Brunet, S; Bueno, J; Carreras, E; Esteve, J; Feliu, E; Guàrdia, R; Julià, A; Llorente, A; Montserrat, E; Oriol, A; Pedro, C; Ribera, JM; Sánchez, JM; Sierra, J; Tormo, M; Vilà, JM; Vivancos, P | 1 |
| Daniel, PT; Dörken, B; Essmann, F; Geilen, CC; Müller, A; Schmelz, K; Schulze-Osthoff, K; Tamm, I; Wieder, T | 1 |
| Abrahams, L; du Toit, C; McDonald, A; Novitzky, N; Thomas, V | 1 |
| Daenen, S; Ferrant, A; Huijgens, PC; Kramer, MH; Löwenberg, B; Schouten, HC; Sonneveld, P; Steijaert, MM; van den Berg, E; van der Holt, B; van Marwijk Kooy, R; Verdonck, LF; Verhoef, GE; Wijermans, PW | 1 |
| Abdel-Latif, ME; Ariffin, H; Ariffin, WA; Chan, LL; Lin, HP | 1 |
| Addamo, B; Benner, A; Biedermann, HG; del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Griesinger, F; Grimminger, W; Haas, R; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Mergenthaler, HG; Pralle, H; Preiss, J; Salwender, H; Schlenk, RF; Schoch, R; Waterhouse, C | 1 |
| Bérard, E; Dageville, C; Dreano, M; Frelin, C; Griessinger, E; Hummelsberger, M; Imbert, V; Peyron, AC; Peyron, JF; Philip, P; Rochet, N; Sirvent, A; Sirvent, N | 1 |
| Allen, SL; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Hoke, E; Hurd, DD; Kolitz, JE; Larson, RA; Moore, JO; Powell, BL; Shea, TC; Vardiman, JW; Velez-Garcia, E | 1 |
| Braess, J; Büchner, T; Fiegl, M; Hiddemann, W | 1 |
| Felix, CA; Libura, J; Richardson, C; Slater, DJ | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Kalaycio, M | 1 |
| Avalos, BR; Blum, W; Bolwell, BJ; Byrd, JC; Copelan, E; Elder, PJ; Farag, SS; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R | 1 |
| Naito, K; Ohnishi, K | 1 |
| Bryantsev, AL; Eggen, BJ; Geugien, M; Kampinga, HH; Schepers, H; van der Toorn, M; Vellenga, E | 1 |
| Billi, AM; Bortul, R; Cappellini, A; Conte, R; Grafone, T; Mantovani, I; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL | 1 |
| Cedrone, M; Chierichini, A; Diverio, D; Foà, R; Lo Coco, F; Mariani, G; Pasquini, L; Pelosi, E; Peschle, C; Riccioni, R; Rossini, A; Saulle, E; Testa, U; Vitale, A | 1 |
| Fonatsch, C; Gaiger, A; Jäger, U; Kainz, B; Schwarzinger, I; Sperr, WR | 1 |
| Botton, Sd; Chelghoum, Y; Dhedin, N; Dombret, H; Dreyfus, F; Elhamri, M; Fenaux, P; Guerci, A; Le, Q; Michallet, M; Pautas, C; Pigneux, A; Raffoux, E; Reman, O; Revel, Td; Thiebaut, A; Thomas, X; Travade, P; Troncy, J; Vekhoff, A | 1 |
| Bloomfield, CD; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Sterling, LJ; Vardiman, JW | 1 |
| Lemez, P; Urbánek, V | 1 |
| Avanzini, P; Baccarani, M; Bocchia, M; Bonini, A; Candoni, A; Castelli, M; Damiani, D; de Vivo, A; Fanin, R; Fiacchini, M; Gugliotta, L; Lauria, F; Malagola, M; Martinelli, G; Mazza, P; Michielutti, A; Ottaviani, E; Piccaluga, PP; Pricolo, G; Raspadori, D; Rondoni, M; Russo, D; Testoni, N; Visani, G; Zaccaria, A; Zuffa, E | 1 |
| Danilatou, V; Kalmanti, M; Mantadakis, E; Papadhimitriou, S; Paterakis, G; Stiakaki, E | 1 |
| Aouali, N; Bonhoure, E; Cuvillier, O; Kohama, T; Levade, T; Morjani, H; Pchejetski, D | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Apostolidis, I; Arvanitopoulou, E; Asprogeraka, T; Bakiri, M; Giannakoulas, N; Kotsianidis, I; Marinakis, T; Matsouka, P; Pagoni, M; Papaioannou, M; Skandali, A; Spanoudakis, E; Tsatalas, K; Viniou, N; Yataganas, X; Zikos, P | 1 |
| Eden, OB; Ng, A; Taylor, GM | 1 |
| Benner, A; Biedermann, HG; Del Valle, F; Döhner, H; Döhner, K; Fischer, JT; Fröhling, S; Glasmacher, A; Götze, K; Haase, D; Hartmann, F; Hensel, M; Kirchen, H; Koller, E; Kremers, S; Matzdorff, A; Mergenthaler, HG; Nerl, C; Pralle, H; Salwender, H; Schlenk, RF; Schoch, R | 1 |
| de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K | 1 |
| Hanada, R; Horibe, K; Kobayashi, R; Tawa, A; Tsuchida, M; Tsukimoto, I | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Hanada, R; Kigasawa, H; Kinoshita, A; Tabuchi, K; Tomizawa, D; Tsuchida, M; Tsukimoto, I | 1 |
| Brandalise, SR; Matsuda, EI; Nowill, AE; Oliveira, SN; Rodrigues, PC; Viana, MB; Yunes, JA | 1 |
| Adamo, F; Amadori, S; Beeldens, F; Berneman, Z; de Witte, T; Fazi, P; Fillet, G; Jehn, U; Lefrère, F; Leone, G; Mandelli, F; Marie, JP; Montanaro, M; Muus, P; Nobile, F; Ricciuti, F; Rizzoli, V; Suciu, S; Thomas, X; Willemze, R | 1 |
| Askin, FB; Bhatia, S; Burden, L; Chen, Z; Dickman, PS; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Perlman, EJ; Rausen, AR; Robison, LL; Vietti, TJ | 1 |
| Adams, JA; Liu, JA; Morris, KL | 1 |
| Imashuku, S | 1 |
| Chantry, AD; Craddock, C; Craig, JI; Marks, DI; Orchard, K; Pearce, RM; Peggs, K; Roddie, C; Snowden, JA; Towlson, KE | 1 |
| Ahmad, I; André, M; Bennani, J; Bron, D; Dargent, JL; Meuleman, N; Ngirabacu, MC; Ravoet, C; Ysebrant, L | 1 |
| Amadori, S; Broccia, G; de Witte, T; Feremans, W; Fillet, G; Jehn, U; Leone, G; Meloni, G; Rio, B; Suciu, S; Thomas, X; Vignetti, M | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Höglund, M; Nahi, H; Paul, C; Sirsjö, A; Tidefelt, U; Tina, E; Uggla, B | 1 |
| Arcaro, A; Doepfner, KT; Spertini, O | 1 |
| Genev, ED; Grudeva-Popova, JG; Lazarova, A; Mumdjiev, IN; Spasova, MI; Stoyanova, AA | 1 |
| Aker, M; Charit, M; Pe'er, J; Pèer, J; Revel-Vilk, S; Weintraub, M | 1 |
| Ates, H; Pehlivan, M; Sercan, HO; Sercan, Z; Simsek, O | 1 |
| Iida, H; Ohkochi, E; Sakurai, Y; Tsukagoshi, S; Tsuruo, T | 1 |
| Glode, LM; Mughal, TI; Robinson, WA; Thomas, MR | 1 |
| Darlow, S; Hamblin, TJ; Mufti, GJ; Nightingale, A; Oscier, DG | 1 |
| Aiba, K; Chinen, T; Kobayashi, T; Kuraishi, Y; Mashizu, N; Meguro, S; Nagamine, D; Ozeki, H; Takasaki, N; Yokoyama, K | 1 |
| Zittoun, R | 1 |
| Cherepanova, VV; Gliasova, GA; Isaev, VG; Kaporskaia, TS; Kulikov, SM; Medvedeva, NV; Parovichnikova, EN; Rekhtman, GB; Savchenko, VG; Tikhonova, LIu | 1 |
| Acolet, D; Deane, M; Murray, NA; Price, J; Roberts, IA | 1 |
| Andrews, R; Begent, RH; Boshoff, C; Holden, L; Newlands, ES; Oliver, RT; Ong, J; Rustin, GJ; Skelton, M | 1 |
| Davison, G; Jacobs, P; Kelly, S; McLellan, G; Pillay, Y | 1 |
| Behm, FG; Boyett, JM; Hancock, ML; Krance, RA; Mahmoud, HH; Pui, CH; Raimondi, SC; Relling, MV; Ribeiro, RC; Sandlund, JT | 1 |
| Creutzig, U; Harbott, J; Löffler, H; Ludwig, WD; Riehm, H; Ritter, J; Schellong, G; Sperling, C; Zimmermann, M | 1 |
| Bullorsky, EO; Ceresetto, JM; Pest, P; Peters, RA; Shanley, CM; Stemmelin, GR | 1 |
| Appelbaum, FR; Buckner, CD; Chauncey, T; Demirer, T; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R; Weaver, CH | 1 |
| Chresta, CM; Francis, GE; Hall, BF | 1 |
| Aster, JC; Inhorn, RC; Roach, SA; Slapak, CA; Soiffer, R; Stone, RM; Tantravahi, R | 1 |
| Kataoka, S; Kawai, H; Mashima, T; Naito, M; Tsuruo, T | 1 |
| Felix, CA; Hosler, MR; Lange, BJ; Masterson, M; Wilson, AE; Winick, NJ | 1 |
| Caporale, R; Cervi, L; Ciolli, S; Giuliani, G; Leoni, F; Pascarella, A; Rossi Ferrini, P; Salti, F | 1 |
| Archimbaud, E; Cordonnier, C; Dreyfus, F; Fenaux, P; Jaubert, J; Leblond, V; Michallet, M; Thomas, X; Travade, P; Troussard, X | 1 |
| Brown, RA; Collins, RH; Fay, JW; Greer, J; Herzig, GP; Herzig, RH; Lynch, JP; Pineiro, L; Stevens, D; Wolff, SN | 2 |
| Mehta, J; Philpott, N; Powles, R; Treleaven, J | 1 |
| Yung, BY | 1 |
| Cassileth, PA; Friedenberg, WR; Hocking, WG; Marx, JJ; Mazza, JJ; Mercier, RJ; Miller, HJ; Raich, PC; Reding, DJ; Schloesser, LL | 1 |
| Ashihara, E; Fujita, N; Goto, H; Hirata, T; Inaba, T; Nakagawa, M; Okawa, K; Oku, N; Shimazaki, C; Yamagata, N | 1 |
| Joseph, PE; Nusbaum, NJ | 1 |
| Kataoka, S; Naito, M; Tomida, A; Tsuruo, T | 1 |
| Archimbaud, E; Auzanneau, G; Cony-Makoul, P; Cordonnier, C; Dombret, H; Dreyfus, F; Fenaux, P; Leblond, V; Stoppa, AM; Troussard, X | 1 |
| Cherepanova, VV; Isaev, VG; Kaporskaia, TS; Kliasova, GA; Kulikov, SM; Medvedeva, NV; Parovichnikova, EN; Rekhtman, GB; Savchenko, VG; Tikhonova, LIu | 1 |
| Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Reifke, J; Stockschläder, M; Zander, A | 1 |
| Kiss, C | 1 |
| Goodin, S; Gosland, M; Hoffman, T; Tsuboi, C; Vore, M | 1 |
| Hashimoto, S; Jing, Y; Nakajo, S; Nakaya, K | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Almqvist, A; Hallman, H; Honkanen, T; Järvenpää, E; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Ruutu, T | 1 |
| Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B | 1 |
| Cerutti, I; Fernández-Barbieri, MA; Gomel, M; Kvicala, R; Matus-Ridley, M; Negri-Aranguren, P; Rosso, A; Sackmann-Muriel, F; Santarelli, MT | 1 |
| Chan, JC; Chan, JK; Lam, SY; Wong, KF | 1 |
| Bell, B; Bernstein, ML; Buchanan, GR; Devine, S; Dreyer, Z; Grier, H; Krischer, J; Kung, F; Land, V; Whitehead, VM | 1 |
| Carter, C; Hodges, S; Lee, EJ; Reck, K; Schiffer, CA | 1 |
| Damon, LE; Linker, CA; Ries, CA; Rugo, HS; Wolf, JL | 2 |
| Borowitz, MJ; Bowman, WP; Buchanan, GR; Jacaruso, D; Kamen, BA; McKenna, RW; Schneider, NR; Shuster, JJ; Winick, NJ | 1 |
| Darbyshire, PJ; Mann, JR; Sartori, PC; Stevens, MC; Taylor, MH | 1 |
| Mayer, RJ; Stone, RM | 1 |
| Cazenave, L; Gehan, E; Heyn, R; Khan, FM; Maurer, HM; Rubinstein, L; Smith, MA; Ungerleider, RS | 1 |
| Comelli, A; De Bernardi, B; Haupt, R; Rosanda, C; Sessarego, M | 1 |
| Adamczyk-Cioch, MB; Dmoszyńska, A; Hus, I; Hus, M | 1 |
| Béhar, C; Benoit, Y; Bertrand, Y; Boutard, P; Ferster, A; Lutz, P; Manel, AM; Otten, J; Robert, A; Solbu, G; Suciu, S; Tokaji, E; Vilmer, E | 1 |
| Dann, EJ; Gillis, S; Rund, D | 1 |
| Akiyama, H; Kanda, Y; Onozawa, Y; Sakamaki, H; Sasaki, T; Takamoto, S; Tanikawa, S | 1 |
| Chubachi, A; Endo, K; Kuriya, S; Maruyama, Y; Meguro, K; Narigasawa, Y; Sasaki, H; Sato, S; Shiga, T; Takami, H | 1 |
| Bishop, JF; Bradstock, K; Cobcroft, R; Enno, A; Fox, R; Garson, OM; Gillett, A; Herrmann, R; Joshua, D; Juneja, S; Lowenthal, RM; Matthews, JP; Page, F; Szer, J; Van Der Weyden, M; Wolf, MM; Young, GA | 1 |
| Bow, EJ; Clinch, JJ; Kilpatrick, MG; Rubinger, M; Schacter, BA; Shore, TB; Sutherland, JA; Williams, GJ | 1 |
| Arthur, DC; Barnard, DR; Buckley, JD; DeSwarte, J; Dusenbery, K; Gold, S; Kalousek, D; Kobrinsky, N; Lange, BJ; Lee, JW; Neudorf, S; Sanders, J; Woods, WG | 1 |
| Amadori, S; Fazi, P; Mandelli, F; Montefusco, E; Petti, MC; Picardi, A; Testi, AM | 1 |
| Huismans, DR; Klumper, E; Loonen, AH; Ossenkoppele, GJ; Pieters, R; Rottier, A; Veerman, AJ; Westra, G | 1 |
| Clausen, N; Hasle, H; Jacobsen, BB; Jacobsen, N; Kerndrup, G; Ostergaard, E; Yssing, M | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Demirer, T; Fefer, A; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R | 1 |
| Belotti, D; Corneo, G; Maffè, PF; Pogliani, EM; Rivolta, GF | 1 |
| Mahendra, P; Marcus, RE; Nacheva, E; Richards, EM; Sinclair, P | 1 |
| Dan, K; Ogata, K; Yamada, T | 1 |
| Allford, S; Glynne, P; Hamblin, M; Horton, C; Mackay, H; Mehta, J; Powles, R; Prendiville, J; Saso, R; Singhal, S; Treleaven, J; Zomas, A | 1 |
| Archimbaud, E; Auzanneau, G; Cony-Makhoul, P; Cordonnier, C; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Leblond, V; Marie, JP; Thomas, X; Tilly, H; Troussard, X | 1 |
| Chen, CL; Fuscoe, JC; Liu, Q; Mahmoud, HH; Pui, CH; Relling, MV | 1 |
| Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA | 1 |
| Davey, MW; Davey, RA; Marks, DC; Su, GM | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Edwards, JR; Gay, JC; Greer, JP; Hord, JD; Janco, RL; Lukens, JN; McCurley, TL; Wells, RJ; Whitlock, JA | 1 |
| Mashima, T; Miller, DK; Naito, M; Nicholson, DW; Noguchi, K; Tsuruo, T | 1 |
| Burnett, AK; Goldstone, AH; Gray, RG; Hann, IM; Rees, JK; Stevens, RF; Wheatley, K | 1 |
| Brinch, L; Evensen, SA; Hedenus, M; Hörnsten, P; Oberg, G; Simonsson, B; Wahlin, A | 1 |
| Galloway, MJ; Hamilton, PJ; Haynes, A; Iqbal, A; Jackson, GH; Proctor, SJ; Russell, N; Taylor, PR; Turner, G | 1 |
| Rowe, JM; Tallman, MS | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Akashi, K; Eto, T; Fujisaki, T; Gondo, H; Harada, M; Harada, N; Hayashi, S; Hirota, Y; Kinukawa, N; Makino, S; Matsuishi, E; Miyamoto, T; Mizuno, S; Murakawa, M; Nagafuji, K; Niho, Y; Ohno, Y; Okamura, T; Shibuya, T; Takamatsu, Y; Takenaka, K; Taniguchi, S; Tanimoto, K; Teshima, T; Yamasaki, K | 1 |
| Akiyama, Y; Bessho, R; Furusho, K; Kataoka, A; Koishi, S; Kubota, M; Lin, YW; Sawada, M; Usami, I; Watanabe, K | 1 |
| Bukh, A; Clausen, N; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T | 1 |
| DeJesus, A; Early, J; Giovanella, B; Pantazis, P | 1 |
| Bishop, JF; Bradstock, K; Lowenthal, RM; Matthews, JP; Young, GA | 1 |
| Allen, SL; Amrein, PC; George, SL; Lee, EJ; Paciucci, PA; Schiffer, CA | 1 |
| Adjei, AA; Ames, MM; Charron, M; Kaufmann, SH; Miller, J; Reid, JM; Rowinsky, EK; Sebolt-Leopold, J; Svingen, PA | 1 |
| Dong, J; Haga, N; Naito, M; Seimiya, H; Tomida, A; Tsuruo, T | 1 |
| Gray, RG; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Dissing, M; Le Beau, MM; Pedersen-Bjergaard, J | 1 |
| Adachi, K; Marunouchi, T; Saito, H; Towatari, M | 1 |
| Burke, PJ; Gore, SD; Weng, LJ | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Brusamolino, E; Canevari, A; Castagnola, C; Castelli, G; Lazzarino, M; Pagnucco, G | 1 |
| Bow, EJ; Gallant, G; Rubinger, M; Schacter, BA; Shore, TB; Williams, GJ; Woloschuk, D | 1 |
| Friedenberg, WR | 1 |
| Beyer, J; Biron, P; Bokemeyer, C; Droz, JP; Fléchon, A; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Schmoll, HJ; Schöffski, P | 1 |
| Brunner, R; Filipits, M; Lechner, K; Pirker, R; Suchomel, RW; Zöchbauer, S | 1 |
| Baak, JP; Broxterman, HJ; Eekman, CA; Feller, N; Klumper, E; Kuiper, CM; Ossenkoppele, GJ; Pieters, R; Schuurhuis, GJ; van Heijningen, TH | 1 |
| Burke, PJ; Cowan, K; Gore, SD; Jones, RJ; Piantadosi, S; Weng, LJ; Zilcha, M | 1 |
| De La Rubia, J; Gomis, F; González-García, Y; Jarque, I; Martín, G; Pérez-Sirvent, M; Sanz, MA; Sempere, A; Senent, L | 1 |
| Britos-Bray, M; Cao, W; Civin, CI; Friedman, AD; Liu, PP; Ramirez, M; Wang, X | 1 |
| Avramis, VI; Carcich, S; Ortega, JA; Ozkaynak, MF | 1 |
| Hirata, S; Katoh, O; Kobayashi, M; Kuramoto, K; Mihara, K; Oguri, T; Takahashi, T; Watanabe, H | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Advani, R; Davis, E; Dugan, K; Greenberg, PL; Litchman, M; Lum, B; Paietta, E; Ramek, J; Rowe, JM; Saba, HI; Sikic, BI; Tallman, MS; Villena, J; Wiernik, PH | 1 |
| Bennett, JM; Lee, S; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS; Wiernik, PH | 1 |
| Berger, C; Braumann, D; de Witt, M; Erttmann, R; Fiedler, W; Grimm, J; Horstmann, M; Hossfeld, KD; Illiger, HJ; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Schönrock, P; Stockshläder, M; Weh, HJ; Zander, AR; Zeller, W | 1 |
| Engelhardt, R; Grotz, W; Lübbert, M; Rump, LC; Würthner, J | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Beare, S; Crump, M; Eisenhauer, E; Hedley, D; Lipton, J; Minden, M; Shepherd, F; Stewart, K; Sutton, D | 1 |
| Altés, A; Brunet, S; Guardia, R; Martino, R; Sierra, J; Sureda, A | 1 |
| Legrand, O; Marie, JP; Zittoun, R | 1 |
| Kawaguchi, M; Nakamura, A; Tsurusawa, M | 1 |
| Atwater, SK; Carlson, KM; Gratiot, M; Jacks, T; Le Beau, MM; Mahgoub, N; Shannon, KM; Taylor, BR | 1 |
| Amadori, S; Archimbaud, E; Belhabri, A; De Cataldo, F; Fillet, G; Jehn, U; Martin, C; Peaud, PY; Thomas, X; Willemze, R | 1 |
| Manabe, T; Sadahira, Y; Sugihara, T; Yawata, Y | 1 |
| Cavaliere, M; Clavio, M; Gobbi, M; Miglino, M; Pierri, I; Pietrasanta, D | 1 |
| Bader, P; Beck, JF; Brügger, D; Denzlinger, C; Einsele, H; Gekeler, V; Herbart, H; Klingebiel, T; Liu, C; Niethammer, D; Orlikowsky, T; Seitz, G | 1 |
| Fadeel, B; Hassan, Z; Hellström-Lindberg, E; Henter, JI; Orrenius, S; Zhivotovsky, B | 1 |
| Gallagher, RE; Huang, XJ; Klein, RS; Wiernik, PH | 1 |
| Ehninger, G; Illmer, T; Neubauer, A; Nowak, R; Oelschlägel, U; Renner, U; Schaich, M; Subat, S; Ziegs, B | 1 |
| Fadeel, B; Hassan, Z; Hellström-Lindberg, E; Zhivotovsky, B | 1 |
| Archimbaud, E; Bordessoule, D; Cony-Makhoul, P; Cordonnier, C; de Revel, T; Delair, S; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Janvier, M; Leblond, V; Marie, JP; Nicolini, F; Rousselot, P; Simon, M; Stoppa, AM; Thomas, X; Tilly, H; Troussard, X; Vekhoff, A | 1 |
| Borisenko, GG; Fabisiak, JP; Kagan, VE; Thampatty, P; Tyurin, VA; Tyurina, YY; Yalowich, JC | 1 |
| Isaev, VG; Khoroshko, ND; Kliasova, GA; Kulikov, SM; Maslova, ER; Ol'shanskaia, IuV; Parovichnikova, EN; Pivnik, AV; Savchenko, VG; Tikhonova, LIu | 1 |
| Gherlinzoni, F; Isidori, A; Lemoli, R; Leopardi, G; Martinelli, G; Motta, M; Pastano, R; Piccaluga, P; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Bishop, JF; Bradstock, KF; Cobcroft, R; Eliadis, P; Enno, A; Gill, D; Herrmann, RP; Juneja, S; Lowenthal, RM; Manoharan, A; Matthews, JP; Page, FJ; Rooney, KF; Rosenfeld, D; Seldon, M; Taylor, KM; Wolf, MM; Young, GA | 1 |
| Kulkarni, S; Mehta, J; Min, T; Powles, R; Saso, R; Singhal, S; Swansbury, GJ; Treleaven, J | 1 |
| Adachi, K; Asou, N; Hatake, K; Hiraoka, A; Jinnai, I; Kageyama, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Matsuda, S; Minami, S; Miyawaki, S; Oh, H; Ohno, R; Ohtake, S; Omoto, E; Saito, K; Sakamaki, H; Shimazaki, C; Takahashi, M; Takeyama, K; Tamura, J; Tanimoto, M; Tsubaki, K; Yamada, O | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Beran, M; Cortes, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Vey, N | 1 |
| Bauer, E; Clark, M; Gieseler, F; Nuessler, V; Valsamas, S | 1 |
| Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP | 1 |
| Bergmann, L; Brack, N; Brockhaus, W; Fischer, JT; Fuhr, HG; Ganser, A; Heil, G; Hoelzer, D; Höffken, K; Hofmann, W; Ittel, TH; Knuth, P; Kolbe, K; Langer, W; Seipelt, G | 1 |
| Abgrall, JF; Audhuy, B; Casassus, P; Deconinck, E; Delain, M; Desablens, B; Guilhot, F; Guyotat, D; Harousseau, JL; Hunault-Berger, M; Le Prise, PY; Lioure, B; Solary, E; Tournilhac, O; Vilque, JP; Witz, B | 1 |
| Addya, K; Cheung, NK; Felix, CA; Jones, DH; Kushner, BH; Lange, BJ; Leonard, DG; Megonigal, MD; Nowell, PC; Rappaport, EF; Williams, TM; Wilson, RB | 1 |
| Brodsky, I; Case, D; Crilley, P; Damon, LE; Linker, CA; Navarro, W; Ries, CA; Rubin, A; Rugo, HS; Sayre, P; Topolsky, D; Wolfe, JL; Zamkoff, K | 1 |
| Appelbaum, FR | 1 |
| Ahmed, T; Baskind, P; Darzynkiewicz, Z; Feldman, EJ; Goff, H; Pozzuoli, M; Santos, S; Seiter, K; Traganos, F | 1 |
| Döhner, H; Döhner, K; Schlenk, RF; van der Reijden, BA | 1 |
| Anderson, JE; Appelbaum, FR; Chauncey, TR; Chen, I; Godwin, JE; Head, DR; Kalaycio, ME; Kopecky, KJ; Kraut, EH; Leith, CP; Luthardt, FW; Moore, DF; Petersdorf, SH; Rankin, C; Shurafa, MS; Willman, CL | 1 |
| Camitta, B; Carroll, AJ; Chang, M; Gresik, MV; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, H | 1 |
| Akiyama, H; Asou, N; Kitamura, K; Kiyoi, H; Kuriyama, K; Kusumoto, S; Minami, S; Miyawaki, S; Motoji, T; Nakano, Y; Naoe, T; Nishimura, M; Ohno, R; Saito, H; Saito, K; Shimazaki, C; Shinagawa, K | 1 |
| Clowes, C; Duarte, R; Pu, QQ; Wang, X | 2 |
| Braumann, D; Colberg, H; del Valle, F; Erttmann, R; Fiedler, W; Finkenstein, F; Holstein, K; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Mayer, U; Metzner, B; Renges, H; Sonnen, R; Sonnenberg, S; Stute, N; Zabelina, T; Zander, AR | 1 |
| Cesaro, S; Chinello, P; Rossi, L; Zanesco, L | 1 |
| Cordone, I; De Cuia, R; Fenu, S; Guerrisi, V; Mandelli, F; Mauro, FR; Meloni, G; Pescarmona, E; Proia, A; Reato, G | 1 |
| Blair, IA; Burden, DA; Felix, CA; Lovett, BD; Megonigal, MD; Osheroff, N; Pang, S; Pommier, YG; Rappaport, EF; Rebbeck, TR; Strumberg, D | 1 |
| al-Ramadi, B; Ellis, M; Gorka, W; Shamoon, A; Zwaan, F | 1 |
| Buckley, DA; du Vivier, AW; Hopster, D; Keane, FM; Mufti, GJ; Munn, SE | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Burnett, AK; Liu Yin, JA; Rees, JK; Wheatley, K | 1 |
| Bishop, JF; Bradstock, KF; Cobcroft, RG; Dodds, AJ; Enno, A; Garson, OM; Gillett, EA; Hermann, RP; Joshua, DE; Juneja, SK; Lowenthal, RM; Ma, DD; Matthews, JP; Szer, J; Taylor, KM; Wolf, M; Young, GA | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Aoudjhane, M; Chéron, N; Deloux, J; Douay, L; Elloumi, M; Fouillard, L; Gorin, NC; Guiguet, M; Isnard, F; Laporte, JP; Lesage, S; Lopez, M; Najman, A; Van Den Akker, J; Zunic, P | 1 |
| Glimelius, B; Kimby, E; Nygren, P | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Behm, FG; Pritchard, M; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Srivastava, DK; Tong, X | 1 |
| Burnett, AK; Clark, RE; Goldstone, AH; Hutchinson, RM; Smith, AG; Wheatley, K | 1 |
| Burnett, AK; Chatters, S; Goldstone, AH; Grimwade, D; Harrison, CJ; Harrison, G; Oliver, F; Walker, H; Wheatley, K | 1 |
| Bensinger, WI; Gooley, T; Heimfeld, S; Holmberg, L; Maloney, D; Rowley, SD; Yu, J | 1 |
| Hara, T; Kanemura, N; Moriwaki, H; Naito, T; Sawada, M; Tsurumi, H; Yamada, T | 1 |
| Akiyama, H; Asou, N; Kiyoi, H; Kodera, Y; Kuriyama, K; Kusumoto, S; Miyawaki, S; Motoji, T; Naoe, T; Nishimura, M; Ohno, R; Saito, H; Saito, K; Shimazaki, C; Shinagawa, K; Tagawa, Y; Ueda, R | 1 |
| Fukuda, N; Muraki, K; Ota, I; Shimohakamada, Y; Shinohara, K | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Hibi, S; Imashuku, S; Ito, E; Kitazawa, J; Kuriyama, K; Morimoto, A; Teramura, T | 1 |
| Becton, DL; Bomgaars, L; Chang, MN; Dahl, GV; Lacayo, NJ; Lauer, SJ; Lum, BL; Ravindranath, Y; Sikic, BI; Weinstein, H | 1 |
| Andresen, S; Elson, P; He, XY; Hussein, M; Kalaycio, M; Lichtin, A; Pohlman, B | 1 |
| Beksac, M; Dalva, K; Hayran, M; Ilhan, O; Koc, H; Konuk, N; Ozcan, M; Sertkaya, D; Topcuoglu, P; Ustün, C | 1 |
| Brighton, T; Kwan, YL; Manoharan, A; Trickett, A | 1 |
| Hon, C; Liang, R; Shek, TW | 1 |
| Wiernik, PH | 2 |
| Gétaz, EP; Staples, WG | 1 |
| Amiel, JL; Berger, R; Rouesse, J | 1 |
| Arnold, AM | 1 |
| Clink, HM; Gerken, ME; McElwain, TJ; Smith, IE | 1 |
| Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J | 1 |
| Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN | 1 |
| Gau, JP; Hu, HT; Hwang, WL; Tsai, YT; Young, JH | 1 |
| Gray, R; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Ekimoto, H; Ikeuchi, T; Iwahashi, T; Mori, S; Okamoto, K; Sugawara, I; Sugimoto, Y; Tsuruo, T | 1 |
| Daugaard, G; Hansen, SW; Larsen, SO; Pedersen-Bjergaard, J; Philip, P; Rørth, M | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, B; Harousseau, JL; Ifrah, N; Leprise, PY; Milpied, N | 2 |
| Ito, T; Ito, Y; Kitaori, K; Nagai, T; Ohno, R; Okumura, M; Sugiura, I; Takeo, T; Yano, K; Yokomaku, S | 1 |
| Benítez, J; Calabuig, T; Outeiriño, J; Pérez Sáenz, MA; Prieto, E; Rodríguez, C; Sánchez Fayos, J | 1 |
| Chou, S; Kaneko, M; Nakamura, Y; Nakaya, K | 1 |
| Dopfer, R; Ehninger, G; Eichel, B; Proksch, B; Schmidt, H; Waidelich, P | 1 |
| Gunji, H; Kharbanda, S; Kufe, D; Rubin, E | 1 |
| Behm, FG; Evans, WE; Hancock, ML; Head, DR; Mahmoud, MH; Pui, CH; Raimondi, SC; Ribeiro, RC; Rivera, GK; Sandlund, JT | 1 |
| Close, P; Meister, L; Ruchelli, E | 1 |
| Ideguchi, H; Kato, S; Muta, K; Nawata, H; Nishimura, J | 1 |
| Farhi, DC; Rosenthal, NS | 1 |
| Ishii, S; Itoh, O; Kariya, Y; Kawaharajo, K; Nagasawa, M; Takeuchi, T; Yamamoto, H | 1 |
| Altschuler, E; Chan, D; Hinds, M; Mayes, J; Zipf, TF; Zwelling, LA | 1 |
| Mivechi, NF; Miyachi, H; Scanlon, KJ | 1 |
| Anderson, K; Coleman, M; Cuttner, J; Schiffer, CA | 1 |
| Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS | 1 |
| Koinumaru, S; Kumano, N; Motomiya, M; Oizumi, K; Saijo, Y; Sugawara, S; Suzuki, S | 1 |
| Jacobs, P | 1 |
| Copplestone, JA; Hamblin, TJ; Mufti, GJ; Oscier, DG | 1 |
| Dalton, RJ; Gerstner, JB; Letendre, L; Levitt, R; Mailliard, JA; Pierre, RV; Therneau, TM | 1 |
| Gross, M; Ross, WE; Yalowich, JC; Zucali, JR | 1 |
17 review(s) available for etoposide and Leukemia, Myeloid
| Article | Year |
|---|---|
Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia.
Topics: Antineoplastic Agents; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Hydatidiform Mole; Incidence; Leukemia, Myeloid; Menopause, Premature; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Stillbirth; Uterine Neoplasms | 2015 |
Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyadenosines; Double-Blind Method; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hypotension; Immunocompromised Host; Leukemia, Myeloid; Male; Mycoses; Neutropenia; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Retrospective Studies; Sepsis; Streptococcal Infections; Viridans Streptococci | 2003 |
Treatment concepts for elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Etoposide; Follow-Up Studies; Forecasting; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Palliative Care; Patient Selection; Randomized Controlled Trials as Topic; Thioguanine; Time Factors | 2003 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Eosinophilia; Etoposide; Fatal Outcome; Female; Humans; Hydroxyurea; Hyperplasia; Ifosfamide; Leukemia, Myeloid; Lymph Nodes; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Syndrome; Translocation, Genetic; Vincristine | 1995 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Transplantation, Autologous | 1993 |
Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Myeloid | 1997 |
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Remission Induction | 1998 |
Role of MRP1 in multidrug resistance in acute myeloid leukemia.
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Chromosomes, Human, Pair 16; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Neoplasm Proteins; Prognosis | 1999 |
Is there a best transplant conditioning regimen for acute myeloid leukemia?
Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Etoposide; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Leukemia, Myeloid; Randomized Controlled Trials as Topic; Thiotepa; Transplantation Conditioning; Whole-Body Irradiation | 2000 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2001 |
Therapy-related myelodysplastic syndrome in a case of cutaneous adult T-cell lymphoma.
Topics: Acute Disease; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Japan; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Lymphoma, T-Cell, Cutaneous; Male; Nitrosourea Compounds; Prednisolone; Proviruses; Radiotherapy; Remission Induction; Translocation, Genetic; Vincristine | 2002 |
Podophyllotoxin derivative VP 16-213.
Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma | 1979 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
123 trial(s) available for etoposide and Leukemia, Myeloid
| Article | Year |
|---|---|
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Gemtuzumab; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid; Liver; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Prospective Studies | 2016 |
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CTLA-4 Antigen; Cytarabine; Disease-Free Survival; Etoposide; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Recurrence; Remission Induction; Young Adult | 2009 |
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Remission Induction; Young Adult | 2009 |
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carbohydrates; Cell Death; Child; Child, Preschool; Citrulline; Cytarabine; Daunorubicin; DNA; Enterocytes; Etoposide; Feces; Female; Humans; Infant; Interleukin-8; Intestinal Absorption; Leukemia, Myeloid; Leukocyte L1 Antigen Complex; Male; Mitoxantrone; Models, Biological; Mucositis; Stomatitis | 2009 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Topics: Acute Disease; Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Remission Induction; Treatment Outcome | 2012 |
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2012 |
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Fever; Humans; Hypotension; Infections; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Treatment Outcome | 2002 |
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemical and Drug Induced Liver Injury; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neutropenia; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Fatigue; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Immunologic Factors; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Life Tables; Middle Aged; Nausea; Neoplasm Proteins; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Immunologic; Receptors, Natural Killer Cell; Recombinant Fusion Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Hyperbilirubinemia; Infection Control; Length of Stay; Leukemia, Myeloid; Male; Neutropenia; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Thrombocytosis; Treatment Outcome | 2002 |
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chemical and Drug Induced Liver Injury; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 2003 |
The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Poland; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 2002 |
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Genetic Markers; Genetic Predisposition to Disease; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Treatment Outcome | 2003 |
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aminoglycosides; Amsacrine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort Studies; Cytarabine; Doxorubicin; Etoposide; Feasibility Studies; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Pilot Projects; Remission Induction; Thioguanine; Vidarabine | 2003 |
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Predictive Value of Tests; Probability; Recurrence; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2003 |
More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Caspase 14; Caspases; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous | 2003 |
Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Thioguanine; Treatment Outcome | 2004 |
Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Prognosis; Recurrence; Risk Factors; Transplantation Conditioning | 2004 |
Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Opportunistic Infections; Remission Induction; Survival Analysis | 2004 |
Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Data Collection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Longitudinal Studies; Melphalan; Middle Aged; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2004 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Treatment Outcome | 2005 |
[Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male | 2004 |
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cranial Irradiation; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Infant; Injections, Spinal; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Risk Assessment; Treatment Outcome | 2004 |
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Remission Induction; Transplantation, Autologous | 2004 |
Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Regression Analysis; Survival Analysis; Treatment Outcome | 2004 |
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous; Tretinoin | 2004 |
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
Topics: Acute Disease; Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Risk; Survival Analysis | 2005 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
Induction chemotherapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2005 |
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2005 |
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Greece; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Societies, Medical; Survival Analysis; Treatment Outcome | 2006 |
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.
Topics: Acute Disease; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2006 |
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Mitoxantrone; Thioguanine; Treatment Outcome; United Kingdom | 2006 |
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Down Syndrome; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Infant; Infections; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Vincristine | 2007 |
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Intravenous; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pancytopenia; Patient Compliance; Risk Factors | 2006 |
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Incidence; Infant; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Neural Tube Defects; Neuroectodermal Tumors, Primitive; Proportional Hazards Models; Risk; Sarcoma, Ewing; Vincristine | 2007 |
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
[The results of 2 and 1/2 years of work of the Russian Multicenter Trial on the Treatment of Acute Myeloid Leukemias in Adults].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Remission Induction; Russia; Survival Analysis; Time Factors | 1995 |
L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Humans; Infant; Karyotyping; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone | 1995 |
Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
Topics: Acute Disease; Adolescent; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Chromosome Aberrations; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Immunophenotyping; Infant; Leukemia, Myeloid; Neoplastic Stem Cells; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Sensitivity and Specificity; Treatment Outcome | 1995 |
Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results.
Topics: Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Survival Rate | 1995 |
High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Middle Aged; Salvage Therapy; Survival Analysis; Treatment Outcome; United States; Whole-Body Irradiation | 1995 |
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Outcome | 1994 |
The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Rate | 1995 |
[The results of a multicenter cooperative study on treating acute myeloid leukemias in adults].
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Russia | 1994 |
Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Hodgkin Disease; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Stomatitis | 1994 |
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia, Myeloid; Male; Remission Induction; Thioguanine | 1994 |
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Survival Analysis | 1993 |
Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Analysis | 1993 |
Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Child; Drug Tolerance; Etoposide; Humans; Ifosfamide; Leukemia, Myeloid; Mesna; Neoplasm Recurrence, Local; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Urinary Tract | 1993 |
A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1993 |
Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Heart; Heart Function Tests; Humans; Infant; Leukemia, Myeloid; Male; Mitoxantrone; Prognosis; Thioguanine; Vincristine | 1996 |
Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hepatic Veno-Occlusive Disease; Humans; Hyperbilirubinemia; Immunologic Factors; Leukemia, Myeloid; Leukopenia; Male; Middle Aged; Premedication; Salvage Therapy | 1996 |
[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy | 1995 |
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Diseases; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Eye Diseases; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Intestinal Mucosa; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Quality of Life; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Life Tables; Male; Prospective Studies; Remission Induction; Survival Analysis; Survival Rate; Thioguanine; Treatment Outcome | 1996 |
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Myelodysplastic Syndromes; Platelet Count; Remission Induction; Thioguanine; Treatment Outcome | 1996 |
High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Graft vs Host Disease; Humans; Leukemia, Myeloid; Middle Aged; Prognosis; Whole-Body Irradiation | 1996 |
Anthracycline drugs and MDR expression in human leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Aberrations; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
[Low-dose chemotherapy].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Remission Induction | 1996 |
Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction | 1996 |
Timed sequential chemotherapy for advanced acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1996 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Recurrence; Risk; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
Topics: Acute Disease; Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Child, Preschool; Contraindications; Cytarabine; Etoposide; Female; Humans; Infant; Infections; Leukemia, Myeloid; Male; Salvage Therapy; Treatment Outcome | 1997 |
Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medica
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Hydrocortisone; Infant; Leukemia, Myeloid; Life Tables; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome | 1997 |
Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cause of Death; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Probability; Remission Induction; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome | 1997 |
Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Remission Induction | 1998 |
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1998 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Patient Compliance; Recurrence; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1998 |
Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gene Rearrangement; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 1998 |
Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Tolerance; Etoposide; Female; Humans; Idarubicin; Intestinal Mucosa; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome; Xylose | 1998 |
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cell Line; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cells; Humans; Immunophenotyping; Infusions, Intravenous; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Growth Factor; Remission Induction | 1995 |
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cardiovascular Diseases; Cohort Studies; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Recombinant Proteins; Remission Induction; Treatment Outcome | 1999 |
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Time Factors; Transplantation, Homologous | 1997 |
Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; DNA Topoisomerases, Type II; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Topotecan | 1999 |
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Combined Modality Therapy; Cytarabine; Diarrhea; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Neutropenia; Remission Induction; Salvage Therapy; Treatment Outcome | 1999 |
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with
Topics: Acute Disease; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Double-Blind Method; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pilot Projects; Transplantation, Autologous | 1999 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Disease-Free Survival; Drug Synergism; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence | 1999 |
[Results of clinical trials in the treatment of acute myeloid leukemia in adults during a 7-year period].
Topics: Acute Disease; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Time Factors; Treatment Outcome | 1999 |
A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Survival Rate | 1999 |
The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Middle Aged; Multivariate Analysis; Remission Induction; Treatment Outcome | 1999 |
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 1999 |
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 1999 |
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1999 |
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Idarubicin; Immunotherapy; Interleukin-2; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Survival Rate | 2000 |
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Recombinant Proteins; Remission Induction; Treatment Outcome | 2000 |
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytapheresis; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 2000 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Conjunctivitis; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Remission Induction; Risk; Stomatitis; Stroke Volume; Survival Analysis; Survival Rate; Treatment Outcome; Tretinoin; Ventricular Dysfunction, Left | 2000 |
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 2000 |
Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA Mutational Analysis; Etoposide; Female; Gene Deletion; Genes, p53; Humans; Japan; Leukemia, Myeloid; Life Tables; Male; Mercaptopurine; Middle Aged; Mutation; Mutation, Missense; Neoplasm Proteins; Prednisolone; Prognosis; Regulatory Sequences, Nucleic Acid; Single-Blind Method; Survival Analysis; Tumor Suppressor Protein p53; Vincristine | 2000 |
Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Karyotyping; Lenograstim; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Predictive Value of Tests; Prednisone; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Follow-Up Studies; Gene Deletion; Genotype; Glutathione Transferase; Humans; Isoenzymes; Leukemia, Myeloid; Mercaptopurine; Multivariate Analysis; NAD(P)H Dehydrogenase (Quinone); Neoplasm Proteins; Peroxidase; Polymorphism, Genetic; Prednisolone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Epstein-Barr Virus Infections; Etoposide; Female; Follow-Up Studies; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Risk Assessment | 2002 |
Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cyclosporine; Drug Interactions; Drug Resistance, Multiple; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Mitoxantrone | 2002 |
Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutrophils; Platelet Count; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 2002 |
Podophyllotoxin derivative VP 16-213.
Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma | 1979 |
VP 16-213 in acute myelogenous leukaemia.
Topics: Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Podophyllotoxin; Remission, Spontaneous | 1976 |
Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: progress report on the MRC AML 10 trial. Medical Research Council Working Party on Childhood Leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid; Recurrence; Remission Induction; Thioguanine; United Kingdom | 1992 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival Analysis | 1991 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; New Zealand; Remission Induction; Survival Rate | 1991 |
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Neoplasms, Second Primary; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Risk Factors; Teniposide | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Remission Induction | 1991 |
Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Infusions, Parenteral; Kidney Diseases; Leukemia, Myeloid; Male; Middle Aged | 1985 |
Busulphan versus combination chemotherapy for initial treatment of chronic granulocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects | 1986 |
177 other study(ies) available for etoposide and Leukemia, Myeloid
| Article | Year |
|---|---|
New diarylheptanoids and diarylheptanoid glucosides from the rhizomes of Tacca chantrieri and their cytotoxic activity.
Topics: Antineoplastic Agents, Phytogenic; beta-Glucosidase; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Circular Dichroism; Diarylheptanoids; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Fibroblasts; Gingiva; Glucosides; Glycoside Hydrolases; Heptanes; Humans; Hydrolysis; Leukemia, Myeloid; Molecular Conformation; Molecular Structure; Multienzyme Complexes; Nuclear Magnetic Resonance, Biomolecular; Phenols; Plants, Medicinal; Rhizome; Tumor Cells, Cultured | 2002 |
Acquired Resistance to Shiga Toxin-Induced Apoptosis by Loss of CD77 Expression in Human Myelogenous Leukemia Cell Line, THP-1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Etoposide; Galactosyltransferases; Humans; Leukemia, Myeloid; Shiga Toxin 1; Shiga Toxin 2; THP-1 Cells; Trihexosylceramides | 2018 |
Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytogenetic Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Genotype; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Recurrence; Remission Induction; Risk Factors; Salvage Therapy; Survival Analysis | 2013 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Mangiferin activates Nrf2-antioxidant response element signaling without reducing the sensitivity to etoposide of human myeloid leukemia cells in vitro.
Topics: Antioxidant Response Elements; Cell Line, Tumor; Etoposide; HL-60 Cells; Humans; Leukemia, Myeloid; NF-E2-Related Factor 2; Signal Transduction; Xanthones | 2014 |
Glutathione is key to the synergistic enhancement of doxorubicin and etoposide by polyphenols in leukaemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Doxorubicin; Drug Synergism; Etoposide; Glutathione; Humans; Jurkat Cells; Leukemia, Lymphoid; Leukemia, Myeloid; Polyphenols; Topoisomerase II Inhibitors | 2015 |
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Cell Line, Tumor; Cell Proliferation; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Homeodomain Proteins; Humans; Leukemia, Myeloid; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Transcription Factors; Vindesine | 2016 |
Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Drug Evaluation, Preclinical; Drug Synergism; Etoposide; G1 Phase; Humans; Hydroxamic Acids; Leukemia, Myeloid; S Phase; Tumor Cells, Cultured; Vorinostat | 2009 |
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoquinones; Cell Line, Tumor; Etoposide; Female; Gene Expression Regulation, Leukemic; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid; Mice; Mice, SCID; Proteasome Endopeptidase Complex; Protein Interaction Domains and Motifs; Protein Structure, Tertiary; Triazoles; WT1 Proteins | 2010 |
Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Etoposide; Female; Humans; Immunophenotyping; Infant; Killer Cells, Natural; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Methotrexate; Mitoxantrone; Remission Induction; Treatment Outcome | 2011 |
ICER evokes Dusp1-p38 pathway enhancing chemotherapy sensitivity in myeloid leukemia.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Survival; Cyclic AMP Response Element Modulator; Down-Regulation; Doxorubicin; Dual Specificity Phosphatase 1; Dual-Specificity Phosphatases; Enzyme Activation; Etoposide; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mitogen-Activated Protein Kinase Phosphatases; p38 Mitogen-Activated Protein Kinases; Recombinant Proteins; RNA Interference; Staurosporine; Transcription, Genetic; Tumor Cells, Cultured | 2011 |
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Feasibility Studies; Female; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Outpatients; Patient Readmission | 2012 |
Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Chromosome Aberrations; Cohort Studies; Comorbidity; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunophenotyping; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid; Male; Palliative Care; Remission Induction; Retrospective Studies; Serbia; Treatment Outcome | 2012 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Anti-angiogenic activity of the purine analog 6-thioguanine.
Topics: 2-Aminopurine; Acute Disease; Aged; Allantois; Anemia; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cattle; Cell Line, Transformed; Chick Embryo; Chorion; Cytarabine; Daunorubicin; Drug Evaluation; Endothelial Growth Factors; Endothelium, Vascular; Etoposide; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Leukemia, Myeloid; Lymphokines; Male; Mice; Mice, Inbred BALB C; Middle Aged; Neovascularization, Pathologic; Neovascularization, Physiologic; Remission Induction; Stress, Mechanical; Thioguanine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Division; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Thalidomide; Vincristine | 2002 |
Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Headache; Humans; Idarubicin; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Neoplastic Stem Cells; Patient Compliance; Pilot Projects; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Failure; Tretinoin | 2002 |
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Topics: Acute Disease; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cladribine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplastic Stem Cells; Recurrence; Remission Induction; Tetrazolium Salts; Thiazoles; Translocation, Genetic; Trisomy | 2002 |
Etoposide-mediated deregulation of the G2M checkpoint in myeloid leukaemic cell lines results in loss of cell survival.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Etoposide; G2 Phase; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Mitosis; Nucleic Acid Synthesis Inhibitors; Phosphorylation | 2002 |
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; California; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Infant; Leukemia, Myeloid; Male; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Risk Factors; Single-Blind Method; Survival Analysis; Thioguanine; Treatment Outcome | 2003 |
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia.
Topics: Acute Disease; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Case-Control Studies; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Etoposide; Genes, Dominant; Humans; In Vitro Techniques; Interleukin-3; Leukemia, Myeloid; Mutation; Phosphatidylinositol 3-Kinases; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Phosphorylation; src Homology Domains; Transfection; Tumor Cells, Cultured | 2003 |
RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Death; Cell Differentiation; Daunorubicin; Etoposide; Gene Expression Regulation, Neoplastic; Genetic Therapy; HL-60 Cells; Humans; Leukemia, Myeloid; Oligodeoxyribonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; RNA Interference; RNA, Double-Stranded; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2003 |
Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Survival Analysis; Treatment Outcome | 2003 |
Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.
Topics: Acute Disease; Adolescent; Amino Acid Sequence; Child; Child, Preschool; Chromosome Breakage; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; DNA-Binding Proteins; Etoposide; Female; Histone-Lysine N-Methyltransferase; Humans; Infant; Leukemia, Myeloid; Male; Molecular Sequence Data; Myeloid-Lymphoid Leukemia Protein; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nuclear Proteins; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogenes; Transcription Factors; Tumor Cells, Cultured | 2003 |
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIM
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Histocompatibility Testing; Humans; Idarubicin; Leukemia, Myeloid; Living Donors; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Remission Induction; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Palliative Care; Remission Induction; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2003 |
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Salvage Therapy; Treatment Outcome | 2003 |
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteria; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Down Syndrome; Etoposide; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Neutropenia; Prospective Studies; Retrospective Studies; Thioguanine | 2004 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Treatment Outcome | 2004 |
Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis.
Topics: Antibodies, Monoclonal; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Membrane Permeability; Cyclophosphamide; Cytochromes c; Drug Resistance, Neoplasm; Etoposide; fas Receptor; Flow Cytometry; Humans; Jurkat Cells; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Microscopy, Fluorescence; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Transfection | 2004 |
[Testicular cancer with inferior vena caval embolus causing pulmonary embolism following chemotherapy: a case report].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Administration Schedule; Embolism; Etoposide; Humans; Leukemia, Myeloid; Male; Neoplasms, Germ Cell and Embryonal; Pulmonary Embolism; Testicular Neoplasms; Vena Cava Filters; Vena Cava, Inferior | 2004 |
Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Apoptosis; Caspase 3; Caspases; Cytarabine; Enzyme Activation; Etoposide; Fas Ligand Protein; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Membrane Glycoproteins; Middle Aged; Nucleic Acid Synthesis Inhibitors; Treatment Outcome | 2004 |
Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB.
Topics: Adult; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Northern; Caspase 8; Caspases; Cell Death; Cell Line, Tumor; Ceramides; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hodgkin Disease; Humans; Intracellular Membranes; Leukemia, Myeloid; Membrane Potentials; Mitochondria; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Sphingomyelins; Tumor Necrosis Factor-alpha | 2004 |
Treating childhood acute myeloid leukaemia with the AML-BFM-83 protocol: experience in a developing country.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Malaysia; Male; Treatment Outcome | 2004 |
Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Child; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Humans; I-kappa B Kinase; Leukemia, Myeloid; Male; Middle Aged; NF-kappa B; Phosphorylation; Protein Serine-Threonine Kinases; Tumor Cells, Cultured | 2005 |
Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion.
Topics: Acute Disease; Antigens, CD34; Cell Proliferation; Cells, Cultured; Clone Cells; DNA-Binding Proteins; Etoposide; Fetal Blood; Gene Rearrangement; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Proto-Oncogenes; Transcription Factors; Translocation, Genetic | 2005 |
HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun.
Topics: Acute Disease; Adaptor Proteins, Signal Transducing; Apoptosis; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Co-Repressor Proteins; Cyclin-Dependent Kinase Inhibitor p21; Enzyme-Linked Immunosorbent Assay; Etoposide; Heat-Shock Proteins; Humans; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; MAP Kinase Kinase Kinase 5; Molecular Chaperones; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-jun; RNA Interference | 2005 |
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Erythropoietin; Etoposide; HL-60 Cells; Humans; Leukemia; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rotenone; Signal Transduction; Stem Cell Factor; Stem Cells | 2005 |
TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Differentiation; Cell Membrane; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; GPI-Linked Proteins; Granulocytes; HL-60 Cells; Humans; Hydroxyurea; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monocytes; Oncogene Proteins, Fusion; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Fusion Proteins; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors; Tumor Stem Cell Assay; U937 Cells | 2005 |
Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Prognosis; Remission Induction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Tretinoin | 2005 |
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival Analysis | 2005 |
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Topics: Acute Disease; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Oligospermia; Sperm Motility; Spermatozoa | 2005 |
T-cell acute lymphoblastic leukemia relapsing as acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cell Differentiation; Cell Lineage; Core Binding Factor Alpha 2 Subunit; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Diagnosis, Differential; Doxorubicin; Etoposide; Fatal Outcome; Female; Gene Dosage; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Karyotyping; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Neoplastic Stem Cells; Proto-Oncogenes; Recurrence; T-Lymphocyte Subsets; Vincristine | 2007 |
Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1.
Topics: Acute Disease; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Survival; Ceramides; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Leukemia, Myeloid; Mitochondria; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; RNA Interference | 2006 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
Genotoxicity of etoposide: greater susceptibility of MLL than other target genes.
Topics: Core Binding Factor Alpha 2 Subunit; Enzyme Inhibitors; Etoposide; Humans; Leukemia, Myeloid; Mutagenicity Tests; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2006 |
Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Central Nervous System; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gingiva; Humans; Hydrocortisone; Idarubicin; Infant; Infant, Newborn; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Leukemic Infiltration; Male; Methotrexate; Orbit; Prognosis; Remission Induction; Sarcoma, Myeloid; Skin; Testis | 2007 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Humans; Infant; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Translocation, Genetic; WT1 Proteins | 2007 |
Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells.
Topics: Acute Disease; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cytarabine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Etoposide; Gemtuzumab; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 2006 |
Etoposide-related secondary acute myeloid leukemia (t-AML) in hemophagocytic lymphohistiocytosis.
Topics: Acute Disease; Adolescent; Adult; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Lymphohistiocytosis, Hemophagocytic; Male | 2007 |
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Registries; Remission Induction; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; United Kingdom; Whole-Body Irradiation | 2006 |
Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Erythropoietin; Etoposide; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Primary Myelofibrosis; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2006 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antigens, Neoplasm; Blood Cells; Bone Marrow Cells; Cell Survival; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; RNA, Messenger | 2007 |
Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.
Topics: Acute Disease; Antibodies; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Autocrine Communication; Cell Division; Cell Line, Tumor; Cytarabine; Down-Regulation; Etoposide; Humans; Insulin-Like Growth Factor I; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction | 2007 |
Pseudomembranous necrotizing tracheobronchitis caused by Aspergillus spp--contribution of one case with acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Aspergillus; Bronchitis; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myeloid; Lung Diseases, Fungal; Male; Necrosis; Opportunistic Infections; Radiography, Thoracic; Tracheitis | 2006 |
Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Retinal Neoplasms; Retinoblastoma; Treatment Outcome | 2007 |
Induction of apoptosis increases expression of non-canonical WNT genes in myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin D1; Etoposide; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Wnt Proteins | 2007 |
Establishment and properties of vincristine-resistant human myelogenous leukemia K562.
Topics: Cell Line; Cells, Cultured; Clone Cells; Doxorubicin; Drug Resistance; Etoposide; Humans; Leukemia, Myeloid; Maytansine; Vincristine | 1983 |
Tumor lysis syndrome following VP-16-213 in chronic myeloid leukemia in blast crisis.
Topics: Adult; Chromosomes, Human, 21-22 and Y; Etoposide; Fever; Heart Arrest; Humans; Hypocalcemia; Leukemia, Myeloid; Male; Phosphates; Podophyllotoxin; Syncope | 1984 |
Serous effusions in monocytic leukaemias.
Topics: Aged; Ascitic Fluid; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Razoxane | 1984 |
[A case report of chronic myelomonocytic leukemia--therapeutic effect of VP 16-213 and cytosine arabinoside].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Male | 1984 |
Subacute and chronic myelomonocytic leukemia.
Topics: Bone Marrow; Cells, Cultured; Clone Cells; Diagnosis, Differential; Etoposide; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Muramidase; Prognosis; Transcobalamins | 1981 |
Fetal marrow suppression after maternal chemotherapy for leukaemia.
Topics: Acute Disease; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infant, Newborn; Infant, Premature, Diseases; Leukemia, Myeloid; Neutropenia; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects | 1994 |
Secondary tumours following etoposide containing therapy for germ cell cancer.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Cytarabine; Dactinomycin; Dose-Response Relationship, Drug; Etoposide; Germinoma; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Neoplasms, Second Primary; Testicular Neoplasms; Vincristine | 1995 |
CD7 expression does not predict for poor outcome in acute myeloblastic leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Prognosis; Retrospective Studies; Survival Analysis; T-Lymphocyte Subsets | 1995 |
Severe esophageal stricture after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Esophageal Stenosis; Esophagitis; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Leukemia, Myeloid; Melphalan; Middle Aged | 1995 |
Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Recombinant Proteins; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 1995 |
Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II-alpha is an early event in HL-60 human leukaemia cell differentiation: effect on topoisomerase activity and etoposide sensitivity.
Topics: Antigens, Neoplasm; Casein Kinase II; Cell Differentiation; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Activation; Etoposide; Humans; In Vitro Techniques; Isoenzymes; Leukemia, Myeloid; Peptide Mapping; Phorbol Esters; Phosphorylation; Protein Serine-Threonine Kinases; Time Factors; Tretinoin; Tumor Cells, Cultured | 1995 |
Aspartate-based inhibitor of interleukin-1 beta-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Camptothecin; Caspase 1; Cell Cycle; Cell Line; Cysteine Endopeptidases; Cytarabine; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; Kinetics; Leukemia, Myeloid; Time Factors; Tumor Cells, Cultured | 1995 |
ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Combined Modality Therapy; Dactinomycin; DNA-Binding Proteins; Etoposide; Female; Genes; Histone-Lysine N-Methyltransferase; Humans; Infant; Leukemia; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Myelodysplastic Syndromes; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogenes; Radiotherapy; Teniposide; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Whole-Body Irradiation | 1995 |
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Treatment Outcome | 1995 |
Sphinganine potentiation of cellular differentiation induced by various anti-leukemia drugs in human leukemia cell line HL-60.
Topics: Antineoplastic Agents; Calcium; Cell Differentiation; Cell Line; Egtazic Acid; Etoposide; Humans; Leukemia, Myeloid; Protein Kinase C; Sphingosine; Verapamil | 1994 |
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; Etoposide; Female; Flow Cytometry; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Lymphocyte Subsets; Lymphoma; Male; Middle Aged; Nitrosourea Compounds; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Emergence of resistance to VP-16/cisplatin chemotherapy: study in a lymphoblast model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Cisplatin; Drug Resistance, Multiple; Etoposide; Flow Cytometry; Humans; Leukemia, Myeloid; Lymphocytes; Models, Biological; Tumor Cells, Cultured | 1994 |
Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Ethyl Methanesulfonate; Etoposide; Humans; Leukemia, Myeloid; Mutagenesis; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1994 |
[Sequential chemotherapy with or without GM-CSF in acute myeloid leukemia (AML) in the advanced phase: current status of protocols EMA 86 and EMA 91].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Dactinomycin; Drug Administration Schedule; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Methotrexate; Middle Aged | 1994 |
Impaired capacity of multidrug resistance-related cytotoxic drugs to inhibit colony formation of dexamethasone-resistant human leukemic cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Humans; Leukemia, Myeloid; Membrane Glycoproteins; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vincristine | 1993 |
17 beta-estradiol glucuronide: an inducer of cholestasis and a physiological substrate for the multidrug resistance transporter.
Topics: Cholestasis; Doxorubicin; Drug Resistance; Estradiol; Estriol; Etoposide; Humans; Leukemia, Myeloid; Paclitaxel; Sarcoma; Tumor Cells, Cultured; Vinblastine | 1993 |
Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells.
Topics: Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cell Cycle; Cell Differentiation; DNA, Neoplasm; Drug Synergism; Etoposide; Growth Inhibitors; Humans; In Vitro Techniques; Leukemia, Myeloid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured | 1994 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
Acute myeloid leukemia presenting as granulocytic sarcoma of the lung.
Topics: Acute Disease; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Humans; Leukemia, Myeloid; Lung Neoplasms; Male | 1993 |
Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Recurrence; Survival Analysis; Time Factors; Transplantation, Autologous | 1993 |
Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.
Topics: Acute Disease; Adolescent; Bone Marrow; Burkitt Lymphoma; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk; Treatment Outcome | 1993 |
Treatment of childhood acute myeloid leukaemia using the BFM-83 protocol.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Life Tables; Male; Survival Analysis; Treatment Outcome | 1993 |
Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
Topics: Acute Disease; Adult; Child; Clinical Trials as Topic; Etoposide; Humans; Incidence; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin | 1993 |
Acute myeloid leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis of bone.
Topics: Acute Disease; Bone Diseases; Child; Etoposide; Female; Histiocytosis, Langerhans-Cell; Humans; Leukemia, Myeloid; Translocation, Genetic | 1993 |
[Clinical and immunologic characteristics of CD 34 positive acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Humans; Immunophenotyping; Leukemia, Myeloid; Male; Middle Aged; Remission Induction | 1995 |
Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Catheterization, Central Venous; Cross Infection; Cytarabine; Daunorubicin; Disease Susceptibility; Etoposide; Female; Fever; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Patient Discharge; Safety; Treatment Outcome | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzene; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 9; Combined Modality Therapy; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Melphalan; Myelodysplastic Syndromes; Neoplastic Stem Cells; Occupational Diseases; Occupational Exposure; Pancytopenia; Remission Induction; Solvents; Translocation, Genetic; Transplantation, Homologous | 1996 |
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Base Sequence; DNA Primers; DNA, Neoplasm; Etoposide; Exons; Gene Rearrangement; Humans; Leukemia; Leukemia, Myeloid; Molecular Sequence Data; Neoplasms, Second Primary; Sequence Deletion; Time Factors; Tumor Cells, Cultured | 1996 |
Extended multidrug resistance in haemopoietic cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Hematopoietic Stem Cells; HL-60 Cells; Humans; Leukemia, Myeloid; Paclitaxel; Tumor Cells, Cultured; Vinblastine | 1996 |
Actin cleavage by CPP-32/apopain during the development of apoptosis.
Topics: Actins; Apoptosis; Camptothecin; Caspase 1; Caspase 3; Caspases; Cysteine Endopeptidases; Etoposide; Humans; Leukemia, Myeloid; Oligopeptides; Protease Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy.
Topics: Acute Disease; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Survival Analysis | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Role of protein tyrosine phosphorylation in etoposide-induced apoptosis and NF-kappa B activation.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzoquinones; Cytarabine; DNA Fragmentation; Etoposide; Humans; Kinetics; Lactams, Macrocyclic; Leukemia, Myeloid; NF-kappa B; Phosphorylation; Phosphotyrosine; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinones; Rifabutin; Tumor Cells, Cultured | 1998 |
MDR1 gene expression and drug resistance of AML cells.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Genes, MDR; Humans; Lethal Dose 50; Leukemia, Myeloid; Mitoxantrone; Tumor Cells, Cultured | 1998 |
Altered sensitivities to anticancer and differentiation agents in etoposide-resistant human myeloid leukemia U-937 cells.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Differentiation; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Myeloid; Lymphotoxin-alpha; Mice; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Topics: Acridines; Antineoplastic Agents; Cell Survival; Doxorubicin; Etoposide; Humans; Leukemia, Myeloid; Pyrazoles; Saccharomyces cerevisiae; Subcellular Fractions; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1998 |
2-Deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukemia U937 cells with inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Nucleus; Deoxyglucose; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chromosome Inversion; Chromosomes, Human, Pair 16; Etoposide; Female; Gene Rearrangement; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Topoisomerase I Inhibitors | 1998 |
Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line.
Topics: Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blotting, Southern; Cell Survival; Cyclophosphamide; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Humans; Isoenzymes; Leukemia, Myeloid; RNA, Antisense; RNA, Messenger; Tumor Cells, Cultured | 1998 |
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Middle Aged; Neoplasm, Residual; Remission Induction; Tumor Stem Cell Assay | 1998 |
Intensifying induction therapy in acute myeloid leukemia by an infusional chemotherapy schedule.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction | 1998 |
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Etoposide; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Mediastinal Neoplasms; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Retroperitoneal Neoplasms; Retrospective Studies; Testicular Neoplasms | 1998 |
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Humans; KB Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multidrug Resistance-Associated Proteins; Phenotype; Prognosis; Treatment Outcome; Tumor Cells, Cultured | 1995 |
P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cohort Studies; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Genes, MDR; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction | 1998 |
Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Middle Aged; Transplantation, Autologous | 1998 |
CBFbeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Apoptosis; DNA Damage; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Oncogene Proteins, Fusion; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence; Remission Induction | 1998 |
Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Bone Marrow Cells; Carrier Proteins; Caspase 3; Caspases; Cell Survival; Doxorubicin; Endothelial Growth Factors; Etoposide; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Lymphokines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukemia, Myeloid; Leukopenia; Liver; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1999 |
Management of acute myeloid leukaemia following myelodysplastic syndrome in a kidney graft recipient.
Topics: Acute Disease; Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cytarabine; Etoposide; Female; Humans; Idarubicin; Imipenem; Kidney Transplantation; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Thienamycins | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
[The role of mitochondria in apoptosis in U937 and Molt-4 cells: difference in order of mitochondrial membrane potential (delta psi m) reduction and interleukin-1 beta-converting enzyme (ICE) on signal transduction pathway in each cell type].
Topics: Apoptosis; Caspase 1; DNA Fragmentation; Etoposide; Humans; Leukemia, Myeloid; Leukemia, T-Cell; Membrane Potentials; Mitochondria; Signal Transduction; Tumor Cells, Cultured; U937 Cells | 1999 |
Myeloid malignancies induced by alkylating agents in Nf1 mice.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Etoposide; Karyotyping; Leukemia, Myeloid; Mice; Mice, Mutant Strains; Mutation; Nerve Tissue Proteins; Neurofibromin 1; Proteins; Topoisomerase II Inhibitors | 1999 |
Cutaneous granulocytic sarcoma mimicking immunoblastic large cell lymphoma.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Doxorubicin; Etoposide; Flow Cytometry; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Myeloid; Lymph Nodes; Lymphoma, Large-Cell, Immunoblastic; Male; Methotrexate; Microscopy, Electron; Prednisone; Skin Neoplasms; Treatment Outcome; Vincristine | 1999 |
GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged | 1999 |
Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Separation; Cell Size; DNA, Complementary; Etoposide; Flow Cytometry; Humans; Leukemia, Myeloid; Polymerase Chain Reaction; Rhodamine 123; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Cleavage of Bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Line; Etoposide; Humans; Leukemia, Myeloid; Mitochondria; Protease Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2 | 1999 |
Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Enzyme Activation; Etoposide; Humans; Leukemia, Myeloid; Oxides; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1999 |
A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Chromosome Banding; Cytarabine; Daunorubicin; DNA, Complementary; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Leukemic; Genes, MDR; Humans; K562 Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Oligonucleotide Probes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Tumor Cells, Cultured | 1999 |
Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39.
Topics: Actins; Acute Disease; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Apoptosis; Blast Crisis; Caspase Inhibitors; Caspases; Cell Differentiation; Cysteine Proteinase Inhibitors; Cytoskeleton; Erythropoietin; Etoposide; fas Receptor; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tretinoin; Tumor Cells, Cultured | 1999 |
Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach.
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Antioxidants; Ascorbic Acid; Chromans; DNA Topoisomerases, Type II; DNA, Neoplasm; Electrons; Etoposide; Free Radicals; HL-60 Cells; Humans; Hydrogen Peroxide; Leukemia, Myeloid; Oxidation-Reduction; Peroxidase; Phospholipids; Sulfhydryl Compounds; Vitamin E | 1999 |
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Clinical Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Evaluation Studies as Topic; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Apoptosis; Cell Nucleus; Comet Assay; Daunorubicin; DNA; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; fas Receptor; Genes, p53; Humans; Intercalating Agents; Leukemia, Myeloid; Mitochondria; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Southern; Chromosomes, Human, Pair 11; Cisplatin; Cyclophosphamide; DNA-Binding Proteins; Doxorubicin; Etoposide; Exons; Fatal Outcome; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid; Male; Molecular Sequence Data; Myeloid-Lymphoid Leukemia Protein; Nerve Tissue Proteins; Neuroblastoma; Polymerase Chain Reaction; Proto-Oncogenes; Time Factors; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Vincristine | 2000 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA-Binding Proteins; Etoposide; Gene Deletion; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Mitoxantrone; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prognosis; Prospective Studies; Recurrence; Remission Induction | 2000 |
Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Multicenter Studies as Topic; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Risk Factors; Survival Analysis; Thioguanine; Translocation, Genetic; Treatment Failure; Treatment Outcome; United States | 2000 |
Serum ICAM-1 concentrations following conventional dose consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell rescue.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Intercellular Adhesion Molecule-1; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Neutrophils; Recombinant Proteins; Solubility | 2000 |
Expression of CD11b/CD18 on neutrophils after consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; CD18 Antigens; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Macrophage-1 Antigen; Male; Melphalan; Middle Aged; Neoplasm Proteins; Neutropenia; Recombinant Proteins; Remission Induction | 2000 |
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2000 |
Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposide; Fungemia; Humans; Ifosfamide; Immunocompromised Host; Infant; Leukemia, Myeloid; Neutropenia; Saccharomyces cerevisiae; Yeast, Dried | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fatal Outcome; Genetic Predisposition to Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Recombinant Proteins; Risk; Smoking; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2000 |
Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.
Topics: Catechols; Chromosome Breakage; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Stability; Etoposide; Histone-Lysine N-Methyltransferase; Humans; Introns; Leukemia, Lymphoid; Leukemia, Myeloid; Myeloid-Lymphoid Leukemia Protein; Oligonucleotides; Proto-Oncogenes; Quinones; Substrate Specificity; Transcription Factors; Translocation, Genetic | 2001 |
Severe hepatic injury associated with lipid formulations of amphotericin B.
Topics: Adolescent; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Liver; Liver Diseases | 2001 |
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Hidradenitis; Humans; Leukemia, Myeloid; Mitoxantrone | 2001 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Incidence; Leukemia, Myeloid; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Rate; Time Factors; Treatment Failure | 2001 |
Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2001 |
Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Cladribine; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Prognosis; Treatment Outcome | 2001 |
Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis.
Topics: Acute Disease; Adult; Antigens, CD34; Blood Cell Count; Blood Component Removal; Blood Platelets; Cyclophosphamide; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Monocytes; Multiple Myeloma; Paclitaxel; Prospective Studies; Recombinant Proteins; Transplantation, Autologous | 2001 |
Acute myeloid leukemia with t(11;19)(q23;p13) developing in an adult T-cell leukemia patient treated with combined chemotherapy including etoposide.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 19; Etoposide; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myeloid; Middle Aged; Neoplasms, Second Primary; Translocation, Genetic | 2001 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cytarabine; Drug Resistance, Multiple; Etoposide; Female; Fluorescent Dyes; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Rhodamine 123; Treatment Outcome; Tretinoin | 2002 |
Conjunctival chloroma (granulocytic sarcoma).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Conjunctival Neoplasms; Etoposide; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Sarcoma, Myeloid | 2002 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
Chronic myelomonocytic leukaemia: a case report.
Topics: Aged; Chronic Disease; Etoposide; Humans; Leukemia, Myeloid; Male; Podophyllotoxin | 1977 |
[Myelomonocytoid leukemia, abnormal cellular clone with a marker chromosome, evolution with a possible cure].
Topics: Adult; Chromosomes, Human, 21-22 and Y; Clone Cells; Cytodiagnosis; Cytogenetics; Etoposide; Female; Humans; Leukemia; Leukemia, Myeloid | 1978 |
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1992 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 1992 |
DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Survival Analysis | 1992 |
Characterization of an etoposide-resistant human K562 cell line, K/eto.
Topics: Antibodies, Monoclonal; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Leukemia, Myeloid; Tritium; Tumor Cells, Cultured | 1991 |
Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Cisplatin; Cohort Studies; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Neoplasms, Germ Cell and Embryonal; Risk Factors | 1991 |
Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leuke
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Vinca Alkaloids | 1991 |
[Subleukemic acute monophagocytic leukemia. A biological phenotype close to malignant histiocytosis].
Topics: Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Doxorubicin; Etoposide; Female; Giant Cells; Histiocytic Sarcoma; Humans; Leukemia; Leukemia, Myeloid; Phagocytosis; Thioguanine | 1991 |
Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
Topics: Animals; Biomarkers, Tumor; Camptothecin; Cell Differentiation; DNA; DNA Damage; Drug Synergism; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid; Mice; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1991 |
Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution.
Topics: Acute Disease; Adolescent; Adult; Biological Availability; Bone Marrow Transplantation; Chromatography, High Pressure Liquid; Combined Modality Therapy; Etoposide; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage | 1991 |
Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide.
Topics: DNA Damage; DNA-Binding Proteins; Etoposide; Gene Expression Regulation; Humans; Leukemia, Myeloid; Proto-Oncogene Proteins c-jun; Proto-Oncogenes; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 1991 |
Granulocytic sarcoma or large cell lymphoma?
Topics: Biopsy; Child, Preschool; Cyclophosphamide; Daunorubicin; Diagnosis, Differential; Etoposide; Female; Humans; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Methotrexate; Thiotepa; Vincristine | 1991 |
Mechanisms involved in the development of adriamycin resistance in human leukemic cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Division; Cell Line; DNA Topoisomerases, Type I; Doxorubicin; Drug Resistance; Etoposide; Glutathione Transferase; Humans; In Vitro Techniques; Leukemia, Myeloid; Membrane Glycoproteins; Verapamil; Vincristine | 1990 |
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Hyperplasia; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Time Factors | 1991 |
[In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Leukemia, Myeloid; Methotrexate; Mitomycin; Mitomycins; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1990 |
Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
Topics: Amsacrine; Cell Adhesion; Cell Differentiation; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Humans; In Vitro Techniques; Leukemia, Myeloid; Molecular Weight; Nuclear Proteins; Phorbol Esters; Proto-Oncogene Proteins c-myc; RNA, Messenger; Tumor Cells, Cultured | 1990 |
Heat radiosensitization and the level of DNA polymerases alpha and beta of human colony-forming unit-granulocyte-macrophage and myeloid leukemias sensitive and resistant to chemotherapeutic agents.
Topics: Blotting, Northern; Cytarabine; DNA Polymerase I; DNA Polymerase II; Dose-Response Relationship, Radiation; Drug Resistance; Etoposide; Hematopoietic Stem Cells; Hot Temperature; Humans; In Vitro Techniques; Leukemia, Myeloid; Tumor Cells, Cultured; X-Rays | 1990 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine | 1987 |
Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line.
Topics: Cell Division; Cell Line; Drug Resistance; Etoposide; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1989 |
Monocytic skin infiltration in chronic myelomonocytic leukaemia.
Topics: Aged; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Monocytes; Razoxane; Skin Neoplasms | 1986 |
Phase I-II trial of VP-16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Leukemia; Leukemia, Myeloid; Male; Middle Aged; Stomatitis | 1986 |
Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.
Topics: Bone Marrow; Cell Survival; Cells, Cultured; Doxorubicin; Drug Synergism; Etoposide; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Macrophages; Podophyllotoxin; Verapamil; Vincristine | 1985 |